Mayne Pharma Group Limited (MYX) - Research

$0.660
Prices as at 16:40, 18 Apr 2019

MYX Current Share Price+

Current Price $0.660
Open $0.665
High $0.670
Low $0.655
Last Close $0.660
Volume 2574884
Price Movement - ( No change )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

MYX General Information

Mayne Pharma Group Limited
MYX
http://www.maynepharma.com
Pharmaceuticals
1,044
1,583

MYX Company Overview

Business Description

Mayne Pharma Group Limited (MYX) is a pharmaceutical company that develops and manufactures branded and generic products, which it distributes directly or through distribution partners in Australia, USA, Europe and Asia. Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, NC, USA.

MYX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2020 F 60.78 3.87 141.60% 17.05 0.00 0.00% 100.0%
2019 F 25.12 1.60 -61.10% 41.25 0.00 0.00% 100.0%
2018 A 60.47 4.12 -33.30% 17.93 0.00 0.00% 100.0%

MYX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2018 A 2019 F 2020 F 2018 A 2019 F 2020 F 2018 A 2019 F 2020 F
Mayne Pharma Group (MYX) $1,053M -0.5645 0.2021 0.6145 23.1707 19.2754 11.9390 0.00% 0.00% 0.00%
Starpharma (SPL) $470M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

MYX Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.43 19.80 0.84 0.50
Market 0.93 16.70 1.52 1.50
Sector 0.76 26.80 3.25 3.06

MYX Directors

Name Position Start Date
Mr Scott Anthony Richards Chief Executive Officer, Managing Director 13 Feb 2012
Mr Bruce L Mathieson Non-Executive Director 16 Feb 2007
Mr Frank Condella Non-Executive Director 30 May 2018
Mr Ian Frank Scholes Non-Executive Director 17 Oct 2007
Ms Nancy Dolan Non-Executive Director 21 Sep 2016
Hon Ron Best Non-Executive Director 26 Jul 2006
Professor Bruce Gregory Robinson Non-Executive Director 26 Aug 2014
Mr Patrick J Blake Non-Executive Director 28 Jun 2018
Mr Roger Campbell Corbett Non-Executive Director, Non-Executive Chairman 17 Nov 2010

MYX Management

Name Position
Peter Paltoglou Chief Development Officer and Head of M&A
Nick Freeman Chief Financial Officer,Company Secretary
Ilana Stancovski Chief Scientific Officer and Head of European Market Development
Kate Rintoul Executive Vice President and General Counsel
Stefan Cross President International Operations
John Ross President Mayne Pharma USA
Lisa Pendlebury Vice President Investor Relations and Communications

MYX Substantial Shareholders

Holding Name
0 (7.30%) Investors Mutual Limited
0 (6.30%) B L Mathieson

MYX Calendar of Events

Date Event
21 February 2020 Report (Interim)
11 October 2019 Report (Annual)
23 August 2019 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.